key: cord-0801785-xsujmr0r
authors: Kasperkiewicz, M.; Schmidt, E.; Amagai, M.; Fairley, J.A.; Joly, P.; Murrell, D.F.; Payne, A.S.; Yale, M.L.; Zillikens, D.; Woodley, D.T.
title: Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic
date: 2021-03-19
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17207
sha: 1eb9dfb6182632a4536b1726e0f0329005460f49
doc_id: 801785
cord_uid: xsujmr0r

The SARS-CoV-2 pandemic has worsened since publication of our initial recommendations for the management of autoimmune bullous diseases (AIBDs) during the COVID-19 outbreak in April 2020.1 Based on the rapidly emerging increase of knowledge, this consensus of an expanded panel of international AIBD experts perceives as prosecution of the existing recommendations to promote optimal care during the pandemic.

The SARS-CoV-2 pandemic has worsened since the publication of our initial recommendations for the management of autoimmune bullous diseases (AIBDs) during the COVID-19 outbreak in April 2020. 1 Based on the rapidly emerging increase in knowledge, this consensus of an expanded panel of international AIBD experts proposes updated recommendations to promote the optimal care of AIBD patients during the pandemic. The updated scientifically based guidance specifically pertains to the following questions:

What do we recommend for AIBD patients considering the effects of immunomodulating therapy on SARS-CoV-2 infection?

Patients with AIBDs treated with immunosuppressive therapies are generally prone to develop opportunistic infections, 2,3 which raised concerns that they could be more susceptible to SARS-CoV-2 infection and/or have worse COVID-19 outcomes. Nevertheless, patients with AIBDs receiving immunomodulating therapies do not appear to have higher rates of manifest SARS-CoV-2 infection or more severe COVID-19 than the general population according to a systematic review of 732 AIBD patients on various immunomodulating treatments including rituximab. 4 While overall 9.5% of them had COVID-19 symptoms, 0.8% showed severe symptoms requiring hospitalization and 0.4% died of COVID-19, with the latter being elderly people and/or having comorbidities. 4 However, since it has been also reported that patients with AIBDs or rheumatic diseases diagnosed with and dying of COVID-19 were more likely to be receiving rituximab treatment and that each passing month from the last rituximab dose decreased the risk of getting COVID-19 and related hospitalization, 5-7 we currently do not recommend the use of rituximab as maintenance therapy to prevent relapses. This particularly applies to individuals who have not received a SARS-CoV-2 vaccine (see below). Therefore, while the decision to initiate B-cell depletion therapy remains to be made on a case-by-case basis, delays or obstructions in other important immunomodulatory treatments should be avoided during the pandemic, supporting our initial advice. Temporary changes in some immunosuppressive medications are still recommended in patients who have active COVID-19, as detailed in our previously suggested guidelines. 1 What should patients with AIBDs do to protect themselves from SARS-CoV-2 infection?

Patients should continuously follow generally recommended measures to prevent SARS-CoV-2 infection (www.who.int, www.cdc.gov) and preferentially be managed with telemedicine instead of in-person visits where appropriate. The major advance in protection from COVID-19 is the recent advent of mRNA vaccines [from Pfizer-BioNTech and Moderna, authorized by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA)] and adenoviral vector vaccines (from AstraZeneca and Johnson & Johnson, authorized by EMA and/or FDA), which induce an immune response to the SARS-CoV-2 spike protein, while additional vaccines are pending authorization or undergoing testing (www.who.int, www.cdc. gov). Therefore, it is recommended that every AIBD patient without contraindications to vaccination is immunized with one of the authorized vaccines to prevent COVID-19. Since the effect of AIBD treatment on the efficacy of COVID-19 vaccines is widely unknown, it is preferred to vaccinate patients while in remission or before planned immunosuppression, if feasible. In the case of rituximab, it is suggested to complete the entire vaccination series ≥4 weeks prior to the initiation of infusions or 12-20 weeks after completion of a rituximab cycle, 8 but the optimal time points are not clearly defined. Although vaccination is expected to be most effective when immunosuppression is low, we do not advise deliberately decreasing the patients' immunomodulatory medications before or during the vaccination period because of the risk of disease exacerbation.

Finally, it is worth mentioning that the European Academy of Dermatology and Venereology task force has initiated a registry for AIBD patients with confirmed COVID-19 (https://recovab.umcg.nl). This online registry, which is open to physicians worldwide, will help determine how the SARS-CoV-2 infection impacts patients with AIBDs and provide future recommendations.

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

Pemphigoid diseases

COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Letter in Reply: Toward a COVID-19 vaccine strategy for pemphigus patients on rituximab